Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor

• Published in: Clinical pharmacokinetics Vol. 56; no. 12; pp. 1461 - 1478
• Main Authors: Ayalasomayajula, Surya, Langenickel, Thomas, Pal, Parasar, Boggarapu, Sreedevi, Sunkara, Gangadhar
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2017; Springer Nature B.V
• Subjects: Age; Aminobutyrates - pharmacokinetics; Angiotensin Receptor Antagonists - pharmacokinetics; Area Under Curve; Bioavailability; Clinical trials; Drug Combinations; Drug dosages; Drug Interactions; Ethnicity; Heart failure; Heart Failure - drug therapy; Humans; Hypertension; Internal Medicine; Kidney diseases; Liver Diseases; Medicine; Medicine & Public Health; Metabolism; Nervous system; Permeability; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Renal Insufficiency - complications; Review Article; Tetrazoles - pharmacokinetics
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-017-0543-3

Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5–2.0, and 2.0–3.0 h, respectively. With a two-fold increase in dose, an increase in the area under the plasma concentration–time curve was proportional for sacubitril, ~1.9-fold for sacubitrilat, and ~1.7-fold for valsartan in healthy subjects. Following multiple twice-daily administration, steady-state maximum plasma concentration was reached within 3 days, showing no accumulation for sacubitril and valsartan, while ~1.6-fold accumulation for sacubitrilat. Sacubitril is eliminated predominantly as sacubitrilat through the kidney; valsartan is eliminated mainly by biliary route. Drug–drug interactions of sacubitril/valsartan were evaluated with medications commonly used in patients with heart failure including furosemide, warfarin, digoxin, carvedilol, levonorgestrel/ethinyl estradiol combination, amlodipine, omeprazole, hydrochlorothiazide, intravenous nitrates, metformin, statins, and sildenafil. Co-administration with sacubitril/valsartan increased the maximum plasma concentration (~2.0-fold) and area under the plasma concentration–time curve (1.3-fold) of atorvastatin; however, it did not affect the pharmacokinetics of simvastatin. Age, sex, or ethnicity did not affect the pharmacokinetics of sacubitril/valsartan. In patients with heart failure vs. healthy subjects, area under the plasma concentration–time curves of sacubitril, sacubitrilat, and valsartan were higher by approximately 1.6-, 2.1-, and 2.3-fold, respectively. Renal impairment had no significant impact on sacubitril and valsartan area under the plasma concentration–time curves, while the area under the plasma concentration–time curve of sacubitrilat correlated with degree of renal function (1.3-, 2.3-, 2.9-, and 3.3-fold with mild, moderate, and severe renal impairment, and end-stage renal disease, respectively). Moderate hepatic impairment increased the area under the plasma concentration–time curves of valsartan and sacubitrilat ~2.1-fold.